KYMR FY 2023 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$79M+67.8% YoY

Gross Profit

$79M100.0% margin

Operating Income

-$166M-210.6% margin

Net Income

-$147M-187.0% margin

EPS (Diluted)

$-2.52

Cash Flow

Operating Cash Flow

-$103M

Free Cash Flow

-$137M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$576M

Total Liabilities

$181M

Stockholders' Equity

$395M

Cash & Equivalents

$110M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$79M	$47M	+67.8%
Gross Profit	$79M	$47M	+67.8%
Operating Income	-$166M	-$161M	-2.7%
Net Income	-$147M	-$155M	+5.1%